Prognostic Value of PD-L1 in Patients with Hepatocellular Carcinoma

Clin Lab. 2019 May 1;65(5). doi: 10.7754/Clin.Lab.2018.180839.

Abstract

Background: The aim of the study is to investigate whether programmed death ligand l (PD-L1) on tumor cells has prognostic significance in patients with hepatocellular carcinoma.

Methods: A cohort of 143 patients with hepatocellular carcinoma was enrolled. PD-L1 expression was detected by immunohistochemistry. The association of PD-L1 expression with clinical characteristics and survival was analyzed.

Results: PD-L1 positive rate in our study was 13.3% (19/143). None of clinical characteristics, including gender, age, virus infection, AFP, vascular invasion, tumor size, and number, was significantly associated with PD-L1 expression (p > 0.05). PD-L1 expression was significantly associated with cirrhosis (p = 0.016). PD-L1 expression was not significantly associated with survival (Log-rank p = 0.076; HR: 0.363 p = 0.091).

Conclusions: PD-L1 expression failed to have a markedly significant prognostic association with survival in patients with hepatocellular carcinoma.

MeSH terms

  • Adult
  • Aged
  • B7-H1 Antigen / biosynthesis*
  • Biomarkers, Tumor / biosynthesis*
  • Carcinoma, Hepatocellular / diagnosis
  • Carcinoma, Hepatocellular / metabolism*
  • Cohort Studies
  • Female
  • Humans
  • Immunohistochemistry
  • Kaplan-Meier Estimate
  • Liver Neoplasms / diagnosis
  • Liver Neoplasms / metabolism*
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Prognosis

Substances

  • B7-H1 Antigen
  • Biomarkers, Tumor